FDA grants accelerated approval to AstraZeneca's oral SERD for breast cancer despite advisory panel opposition

FDA granted accelerated approval to AstraZeneca's oral selective estrogen receptor degrader, Camizestrant, for a specific group of breast cancer patients.

The approval was issued on Friday even though the FDA's advisory committee voted against it in April, citing concerns about the supporting data.

Regulators determined that the drug meets the criteria for accelerated approval, allowing it to be marketed while additional confirmatory trials are completed.